發(fā)布時(shí)間：2018-02-14 12:40

  本文關(guān)鍵詞： 干細(xì)胞 間質(zhì)干細(xì)胞移植 肝炎 乙型 組織工程 移植 乙型肝炎 失代償期 恩替卡韋 扶正化瘀膠囊 治療結(jié)果　出處：《中國(guó)組織工程研究》2017年13期 　論文類型：期刊論文

【摘要】：背景:骨髓間充質(zhì)干細(xì)胞在特定環(huán)境下可分化成肝干細(xì)胞,參與肝功能的修復(fù)和重建。目的:分析自體骨髓間充質(zhì)干細(xì)胞移植治療失代償期乙型肝炎的效果。方法:將84例乙型肝炎失代償期患者隨機(jī)分為2組,常規(guī)組(n=42)采用對(duì)癥治療,同時(shí)口服恩替卡韋、扶正化瘀膠囊;干細(xì)胞組(n=42)在常規(guī)組治療的基礎(chǔ)上,經(jīng)肝左右動(dòng)脈移植自體骨髓間充質(zhì)干細(xì)胞1×106/kg。治療前及治療后12,24周,檢測(cè)肝纖維化、肝功能及終末期肝病模型系統(tǒng)評(píng)分,統(tǒng)計(jì)患者1年生存率。結(jié)果與結(jié)論:(1)肝纖維化:兩組治療后的透明質(zhì)酸、層粘連蛋白、Ⅲ型前膠原、Ⅳ型膠原蛋白水平均低于治療前(P0.05);干細(xì)胞組治療后12,24周的上述指標(biāo)均低于常規(guī)組(P0.05);(2)肝功能:兩組治療后的丙氨酸氨基轉(zhuǎn)移酶、天門冬氨酸氨基轉(zhuǎn)移酶、總膽紅素水平均低于治療前(P0.05),白蛋白、膽堿酯酶、凝血酶原活動(dòng)度水平均高于治療前(P0.05);干細(xì)胞組治療后12,24周的丙氨酸氨基轉(zhuǎn)移酶、天門冬氨酸氨基轉(zhuǎn)移酶、總膽紅素水平均低于常規(guī)組,膽堿酯酶水平高于常規(guī)組(P0.05);(3)終末期肝病模型系統(tǒng)評(píng)分:兩組治療后的終末期肝病模型系統(tǒng)評(píng)分均低于治療前(P0.05),干細(xì)胞組治療后24周的終末期肝病模型系統(tǒng)評(píng)分低于常規(guī)組(P0.05);(4)1年生存率:干細(xì)胞組1年生存率高于常規(guī)組(50%,69%,P0.05);(5)結(jié)果表明:采用自體骨髓間充質(zhì)干細(xì)胞移植治療失代償期乙型肝炎,能夠顯著改善肝纖維化狀態(tài)和肝功能,提高患者1年生存率。
[Abstract]:Background: bone marrow mesenchymal stem cells can differentiate into liver stem cells under specific circumstances. Objective: to analyze the effect of autologous bone marrow mesenchymal stem cell transplantation in the treatment of decompensated hepatitis B. methods: 84 patients with decompensated hepatitis B were randomly divided into two groups: control group (n = 42). At the same time, oral entecavir, Fuzheng Huayu capsule and stem cell group were used to detect hepatic fibrosis. On the basis of routine treatment, autologous bone marrow mesenchymal stem cells (BMSCs) were transplanted through left and right hepatic artery at 1 脳 106% kg. before and after treatment for 24 weeks. Results and conclusion liver fibrosis: hyaluronic acid, laminin, type 鈪，

本文編號(hào)：1510726